Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
11.73
Nov 16 • 3:59 PM ET Dollar change-0.77 Percentage change(-6.16%)
Aftermarket Close
11.73
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
998.30M
Enterprise Value
601.46M
Income
-273.48M
Sales
0.00M
Book/sh
4.48
Cash/sh
5.86
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
130
IPO
Oct 20, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
2.62
P/C
2.00
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
9.13
Current Ratio
9.13
Debt/Eq
0.27
LT Debt/Eq
0.26
Option/Short
Yes / Yes
EPS (ttm)
-3.67
EPS next Y
-3.55
EPS next Q
-0.86
EPS this Y
-1.02%
EPS next Y
0.46%
EPS next 5Y
7.76%
EPS past 3/5Y
-27.48% -256.78%
Sales past 3/5Y
- -
EPS Y/Y TTM
-10.20%
Sales Y/Y TTM
-
EPS Q/Q
15.34%
Sales Q/Q
-
Insider Own
11.74%
Insider Trans
-4.50%
Inst Own
85.11%
Inst Trans
13.65%
ROA
-57.27%
ROE
-81.57%
ROIC
-56.71%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-1.60%
SMA50
-0.71%
SMA200
-27.77%
Trades
Shs Outstand
85.11M
Shs Float
75.12M
52W High
23.29 -49.64%
52W Low
9.46 24.00%
Volatility
7.49% 7.65%
ATR (14)
0.84
RSI (14)
48.12
Beta
1.12
Rel Volume
0.86
Avg Volume
1.62M
Volume
1,395,850
Perf Week
-7.05%
Perf Month
22.83%
Perf Quarter
-28.21%
Perf Half Y
-28.65%
Perf YTD
-11.00%
Perf Year
-8.14%
Perf 3Y
-70.89%
Perf 5Y
18.25%
Perf 10Y
-
Prev Close
12.50
Price
11.73
Change %
-6.16%
Consensus
Buy
Avg. Price Target
$32.00
Implied Upside
+172.8%
Analysts11incl. previous ratings
Rating Distribution6 Buy · 4 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 06, 2026Initiated
CChardan Capital Markets
Buy$57+385.9%
Mar 23, 2026Upgrade
WWolfe Research
Underperform → Outperform$24+104.6%
Mar 19, 2026Upgrade
RRothschild & Co Redburn
Neutral → Buy$40+241.0%
Jan 15, 2026Downgrade
GS logoGGoldman
Neutral → Sell$10-14.7%
Jan 09, 2026Upgrade
BBTIG Research
Neutral → Buy$24+104.6%
Nov 03, 2025Upgrade
HH.C. Wainwright
Neutral → Buy$30+155.8%
Oct 02, 2025Downgrade
HH.C. Wainwright
Buy → Neutral
Oct 01, 2025Downgrade
GS logoGGoldman
Buy → Neutral$7-40.3%
Sep 30, 2025Downgrade
WWolfe Research
Outperform → Underperform$2-82.9%
Sep 30, 2025Downgrade
C logoCCitigroup
Buy → Neutral$5-57.4%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Reich KristianChief Scientific OfficerJul 27 '26Sale20.001,10022,0002,711,198Jul 29 04:10 PM
Reich KristianChief Scientific OfficerJul 21 '26Sale20.0250,0001,001,0002,714,746Jul 23 04:05 PM
Reich KristianChief Scientific OfficerJul 22 '26Sale20.002,44848,9602,712,298Jul 23 04:05 PM
Reich KristianChief Scientific OfficerJul 20 '26Sale20.0943,700877,9332,764,746Jul 21 06:13 PM
Reich KristianChief Scientific OfficerJul 15 '26Sale20.0116,105322,2612,808,446Jul 20 06:07 AM
Reich KristianOfficerJul 15 '26Proposed Sale19.44150,0002,916,000Jul 15 04:46 PM
Santos da Silva JorgeChief Executive OfficerJul 10 '26Sale20.0268,2891,367,1462,774,893Jul 13 04:10 PM
Santos da Silva JorgeChief Executive OfficerJul 09 '26Sale20.0133,936679,0592,843,182Jul 13 04:10 PM
Santos da Silva JorgeChief Executive OfficerJul 01 '26Sale20.0347,775956,9332,877,118Jul 02 04:10 PM
Santos da Silva JorgeOfficerJun 30 '26Proposed Sale20.03150,0003,004,500Jun 30 05:15 PM
Bodenstedt MatthiasChief Financial OfficerJun 22 '26Sale22.0439,120862,2051,115,435Jun 23 04:01 PM
Bodenstedt MatthiasChief Financial OfficerJun 17 '26Sale19.6815,082296,8141,157,349Jun 18 06:45 PM
Bodenstedt MatthiasChief Financial OfficerJun 18 '26Sale19.602,79454,7621,154,555Jun 18 06:45 PM
Reich KristianChief Scientific OfficerJun 17 '26Sale19.4350,000971,5002,824,551Jun 17 06:15 PM
Reich KristianChief Scientific OfficerJun 15 '26Sale18.8950,000944,5002,924,551Jun 17 06:15 PM
Reich KristianChief Scientific OfficerJun 16 '26Sale18.7050,000935,0002,874,551Jun 17 06:15 PM
Reich KristianOfficerJun 15 '26Proposed Sale19.00150,0002,850,000Jun 15 05:14 PM
Bodenstedt MatthiasChief Financial OfficerMay 11 '26Sale20.0213,653273,3331,172,431May 13 04:10 PM
Bodenstedt MatthiasChief Financial OfficerApr 14 '26Sale19.562,42647,4531,186,084Apr 16 04:10 PM
Santos da Silva JorgeChief Executive OfficerApr 10 '26Sale18.4198,1271,806,5182,976,766Apr 14 05:55 PM
Santos da Silva JorgeChief Executive OfficerApr 13 '26Sale18.2351,873945,6452,924,893Apr 14 05:55 PM
Bodenstedt MatthiasChief Financial OfficerApr 09 '26Sale18.9485,8701,626,3781,190,435Apr 10 06:06 PM
Bodenstedt MatthiasChief Financial OfficerApr 10 '26Sale19.511,92537,5571,188,510Apr 10 06:06 PM
Jorge Pedro Santos Radeck D SiCEOApr 10 '26Proposed Sale18.58150,0002,787,000Apr 10 09:56 AM
Bodenstedt MatthiasOfficerApr 09 '26Proposed Sale18.46160,8702,969,660Apr 09 04:01 PM
BVF PARTNERS L P/ILDirectorMar 31 '26Sale16.793,750,00062,962,5001,039,238Apr 02 04:48 PM
BVF PARTNERS L P/IL10% OwnerMar 31 '26Proposed Sale16.933,750,00063,487,500Mar 31 09:18 PM
Santos da Silva JorgeChief Executive OfficerDec 08 '25Sale15.08130,0001,960,4002,948,577Dec 10 04:29 PM
Santos da Silva JorgeChief Executive OfficerDec 09 '25Sale14.4970,0001,014,3002,878,577Dec 10 04:29 PM
Reich KristianChief Scientific OfficerDec 08 '25Sale15.08130,0001,960,40072,908Dec 10 04:29 PM
Reich KristianChief Scientific OfficerDec 09 '25Sale14.4372,9081,052,0620Dec 10 04:29 PM
Jorge Pedro Santos Radeck Da SOfficerDec 08 '25Proposed Sale14.90200,0002,980,000Dec 08 10:36 AM
Kristian Dieter Johannes ReichOfficerDec 08 '25Proposed Sale14.80202,9083,003,038Dec 08 10:07 AM
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.
Co-FounderDr. Jorge Santos da Silva Ph.D.
Ph.D.Dr. Kristian Reich M.D.
Chief Financial OfficerMr. Matthias Bodenstedt
Chief Technical OfficerMr. Oliver Daltrop Ph.D.
Director of Investor Relations & External CommunicationsMs. Carla Bretes